Instruction for use: Riabal

Active substance: Prifinium bromide

ATX Code

A03AB18 Prifinium bromide

Pharmacological group

M Cholinolytics

antispasmodics myotropic

The nosological classification (ICD-10)

K52 Other noninfectious gastroenteritis and colitis

senile Bowel Syndrome, sigmoid, Gastroenteritis noninfectious, gastroenterocolitis, Colitis, Colitis non-dysenteric, Colitis noninfectious, Colitis is a chronic, Colitis is a chronic non-infectious, Local enteritis, sigmoid noninfectious, Chronic inflammatory bowel disease, Chronic inflammatory disease of the small intestine, Chronic enterocolitis, Chronic atrophic gastroenteritis, Chronic gastroenteritis, Chronic colitis, Chronic enterocolitis, Enteritis, non-infectious enteritis, Enterocolitis chronic noncommunicable, colon disease

R10.4 Other and unspecified abdominal pain

Abdominal pain, Gastrointestinal spasm, intestinal colic, Colic in infants, The feeling of fullness, Resi abdominal, Spasm of smooth muscle in diseases of the digestive tract, The spasm of the biliary tract, Biliary tract spasm, enterospasm, Spasm of the digestive tract, Spasms of the digestive tract smooth muscle, stomach Cramps, gastrointestinal spasms, Spastic condition of the gastrointestinal tract, intestinal tenesmus, Feeling of fullness, Baby colic

R11 Nausea and vomiting

Postoperative vomiting, Nausea, vomiting, Vomiting in the postoperative period, Vomiting drug, Vomiting on the background radiation therapy, Vomiting indomitable, Vomiting with radiation therapy, persistent vomiting, anacatharsis, Postoperative nausea, Vomiting during chemotherapy, Vomiting of central origin, Vomiting on the background of cytostatic chemotherapy, persistent hiccups, repeated vomiting

R14 Flatulence and related conditions

abdominal distention, flatulence, pronounced flatulence, Gases in the postoperative period, degassing bowel before diagnostic studies, degassing intestine before X-rays, gas delay, Excessive formation and accumulation of gases in the digestive tract, brash, Flatulence, Flatulence with increased gas formation in the digestive tract, Flatulence in infants, Flatulence in newborns, Flatulence caused by fatty or unusual food, Flatulence caused by disease of the digestive tract, belching, The feeling of bloating, The feeling of fullness, Increased flatulence, The increased gas formation and accumulation of gases in the digestive tract, Fullness in the epigastrium, Feeling of fullness, The feeling of heaviness in the stomach, Flatulence in the gastrointestinal tract, Increased production and accumulation of gases in the digestive tract

Structure and Composition

1 ml of oral solution contains 5 mg prifiniya bromide; in vials of 50 ml with 0.4 ml pipette.

pharmachologic effect

Mode of action - antispasmodic, antiemetic.

Blocks peripheral m-cholinergic receptors (including the digestive tract), inhibits gastric acid secretion.

pharmacodynamics

Reduces acid secretion, peptic activity of gastric juice, pancreatic exocrine activity. Reduces the tone of smooth muscles of the digestive tract, promotes gastric emptying, has a corrective influence at elevated motor activity of the digestive tract.

Pharmacokinetics

If ingestion is poorly absorbed from the gastrointestinal tract and does not cross the BBB. Because the body is displayed quickly, mainly with urine and partially with bile.

Indications

Vomiting (functional spasms in infants and children after feeding, acute gastroenteritis, in feverish conditions, with intracranial hypertension, after radiotherapy, intolerance of medicines). Abdominal pain (functional colon diseases, including cross-country and accompanied by abdominal distention disorders). Smooth muscle spasms gastrointestinal psychogenic nature. In addition to the etiological treatment of organic diseases of the gastrointestinal tract.

Contraindications

Angle-closure glaucoma, urinary retention.

Side effects

Rare: dry mouth, mydriasis, disturbance of accommodation, somnolence.

Interaction

It enhances the effect of opioid analgesics, antidepressants, neuroleptics, anti-Parkinsonian agents and atropine.

Dosing and Administration

Inside, children, 3 times a day. The average daily dose - 1 mg / kg body weight (one pipette filled to redline contained 2 mg prifiniya bromide).

Storage conditions

At temperatures below 25 ° C.

Keep out of the reach of children.

Shelf-life

3 years.

Do not use beyond the expiration date printed on the package.